Antibodies: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

Developed by Biogen, the drug, aducanumab, targets a protein called amyloid that forms abnormal deposits in the brains of people with Alzheimer's. The company originally discontinued work on the drug in March 2019 after disappointing trial results. 2019-10-22T00:00:00+0000The drug, crizanlizumab, specifically inhibits selectin, a substance that contributes to cells sticking together and causes vaso-occlusive crisis, an extremely painful condition that is frequently a reason for patients to visit emergency departments. 2019-11-15T00:00:00+0000The drug is enfortumab vedotin-ejfv, an antibody drug conjugate. It was given accelerated approval for adult patients with locally advanced or metastatic urothelial cancer who failed to respond to PD1 immune checkpoint therapy or platinum-containing chemotherapy. 2019-12-18T00:00:00+0000The treatment, developed by Regeneron Pharmaceuticals, contains two monoclonal antibodies: casirivimab and imdevimab. The treatment had been trialled in a a randomised, double-blind, placebo-controlled clinical trial in 799 non-hospitalised adults. 2020-11-21T00:00:00+0000The treatment contains tixagevimab with cilgavimab and is intended for individuals with moderate to severely compromised immune systems or severe adverse reactions to a COVID-19 vaccine. 2021-12-08T00:00:00+0000The drug, bebtelovimab, is a neturalising IgG1 monoclonal antibody that binds to the SARS-CoV-2 spike protein. It was developed by AbCellera and Eli Lilly using a high throughput B-cell screening pipeline. . 2022-02-11T00:00:00+0000
Date Event People Places Sciences
22 Oct 2019Monoclonal drug originally dismissed for treating Alzheimers got new green light from FDA for testing for the disease BiogenMonoclonal antibodies
15 Nov 2019FDA approved first monoclonal antibody drug to help treat painful complications associated with sickle-cell disease NovartisMonoclonal antibodies
18 Dec 2019FDA granted accelerated approval for Seattle Genetics drug for advanced urothelial cancer Seattle GeneticsMonoclonal antibodies, Oncology
21 Nov 2020FDA issued emergency authorisation for the first monoclonal antibody treatment for patients with mild to moderate COVID-19 Regeneron PharmaceuticalsMonoclonal antibodies
8 Dec 2021FDA issued emergency authorisation for long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain patients AstraZenecaMonoclonal antibodies
11 Feb 2022FDA issued emergency use authorisation for a new monoclonal antibody treatment for COVID-19 that is active against the omicron variant.  AbCellera, Eli LillyMonoclonal antibodies

22 Oct 2019

Monoclonal drug originally dismissed for treating Alzheimers got new green light from FDA for testing for the disease

15 Nov 2019

FDA approved first monoclonal antibody drug to help treat painful complications associated with sickle-cell disease

18 Dec 2019

FDA granted accelerated approval for Seattle Genetics drug for advanced urothelial cancer

21 Nov 2020

FDA issued emergency authorisation for the first monoclonal antibody treatment for patients with mild to moderate COVID-19

8 Dec 2021

FDA issued emergency authorisation for long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain patients

11 Feb 2022

FDA issued emergency use authorisation for a new monoclonal antibody treatment for COVID-19 that is active against the omicron variant.

Respond to or comment on this page on our feeds on Facebook, Instagram or Twitter.